B. Riley Expects Reduced Earnings for Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Investment analysts at B. Riley cut their Q2 2025 EPS estimates for Rigel Pharmaceuticals in a report issued on Tuesday, May 6th. B. Riley analyst K. Patel now forecasts that the biotechnology company will post earnings per share of $0.14 for the quarter, down from their prior estimate of $0.18. B. Riley currently has a “Neutral” rating and a $24.00 target price on the stock. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $0.22 per share. B. Riley also issued estimates for Rigel Pharmaceuticals’ Q3 2025 earnings at $0.08 EPS, Q4 2025 earnings at $0.16 EPS and FY2027 earnings at $1.44 EPS.

Several other analysts have also recently issued reports on RIGL. Cantor Fitzgerald increased their target price on Rigel Pharmaceuticals from $20.00 to $23.00 and gave the company a “neutral” rating in a research report on Wednesday. HC Wainwright reissued a “buy” rating and issued a $57.00 target price on shares of Rigel Pharmaceuticals in a research report on Wednesday, March 5th. StockNews.com downgraded shares of Rigel Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 8th. Finally, Citigroup lifted their price target on Rigel Pharmaceuticals from $49.00 to $55.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Rigel Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $36.40.

Rigel Pharmaceuticals Price Performance

Shares of Rigel Pharmaceuticals stock opened at $18.96 on Friday. The stock has a market cap of $338.81 million, a price-to-earnings ratio of 135.46 and a beta of 1.34. The firm’s 50-day moving average is $18.63 and its two-hundred day moving average is $19.76. Rigel Pharmaceuticals has a 1 year low of $7.48 and a 1 year high of $29.82.

Rigel Pharmaceuticals (NASDAQ:RIGL) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.14 by $0.49. The firm had revenue of $53.33 million for the quarter, compared to analyst estimates of $43.87 million. Rigel Pharmaceuticals had a negative return on equity of 14.80% and a net margin of 2.46%. During the same quarter last year, the firm posted ($0.50) earnings per share.

Institutional Trading of Rigel Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. purchased a new stake in Rigel Pharmaceuticals in the fourth quarter valued at $63,000. US Bancorp DE boosted its position in shares of Rigel Pharmaceuticals by 57.4% during the first quarter. US Bancorp DE now owns 5,120 shares of the biotechnology company’s stock worth $92,000 after buying an additional 1,868 shares during the period. New York State Common Retirement Fund lifted its stake in Rigel Pharmaceuticals by 65.9% during the 1st quarter. New York State Common Retirement Fund now owns 5,536 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 2,200 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Rigel Pharmaceuticals by 44.5% during the 4th quarter. Wells Fargo & Company MN now owns 8,603 shares of the biotechnology company’s stock valued at $145,000 after acquiring an additional 2,648 shares during the period. Finally, SG Americas Securities LLC grew its position in Rigel Pharmaceuticals by 42.8% in the 4th quarter. SG Americas Securities LLC now owns 9,429 shares of the biotechnology company’s stock valued at $159,000 after acquiring an additional 2,827 shares in the last quarter. Hedge funds and other institutional investors own 66.23% of the company’s stock.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.